ClinicalTrials.gg
CompletedNCT01507168Updated Apr 3, 2020

A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

A Phase 2 interventional study of Placebo and GC33 in Carcinoma, Hepatocellular, sponsored by Hoffmann-La Roche. Completed at 57 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-03.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
185
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Carcinoma, Hepatocellular by Hoffmann-La Roche — 1 open to participants now, 6 under way, 3 of them phase 3. Carcinoma, Hepatocellular · Hoffmann-La Roche.

Enrollment
6th of 17
185 · median 100
Started
2012
the only one that year
Phase 2
3 of 21
none open now
Registered
3rd of 21
by date

Among the 21 studies in Carcinoma, Hepatocellular by Hoffmann-La Roche, this one is the 6th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2012, is one of 3 in phase 2, and was the 3rd registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

1 of the 21 studies in Carcinoma, Hepatocellular by Hoffmann-La Roche is open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Carcinoma, Hepatocellular by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This randomized, placebo-controlled, multicenter study will evaluate the efficacy and safety of GC33 (RO5137382) in previously treated patients with unresectable advanced or metastatic hepatocellular carcinoma. Participants will be stratified according to the level of GPC-3 expression in tumors and randomized to receive either GC33 (1600 mg intravenously) or placebo on Days 1 and 8 of Cycle 1 and every 2 weeks thereafter. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.

03

Conditions studied

  • Carcinoma, Hepatocellular
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/= 18 years of age
  • confirmed hepatocellular carcinoma (without fibro-lamellar subtype)
  • Prior treatment with at least 1 systemic agent, with documented progressive disease after systemic agent(s), or documented adverse event(s) associated with prior systemic agent(s) that resulted in discontinuance of that (those) agent(s)
  • Not a candidate for curative treatments (e.g. resection, transplantation)
  • A (score of 5-6)
  • (ECOG) performance status 0 or 1
  • Adequate hematologic, hepatic and renal function
  • Ability to provide, for central review, a tumor tissue sample to determine the level of GPC-3 expression by IHC
  • by criteria

Exclusion criteria

Exclusion Criteria:

  • B or C
  • Known hepatocellular carcinoma with fibro-lamellar histology
  • Known brain or
  • Active infectious diseases requiring treatment except for and C
  • History of organ allograft including liver transplant
  • Anticipated or ongoing administration of anticancer therapies other than those administered in this study
  • Anticancer treatment within 2 weeks prior to entering the study
  • Patients who have not fully recovered from toxicities associated with previous HCC loco-regional or systemic therapies
  • Patients receiving interferon therapy
  • Pregnant or lactating women
  • Known positivity or AIDS-related illness
  • History of significant to similar agents (monoclonal antibody, protein-included drugs, Chinese hamster ovary products)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
185 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    GC33 (RO5137382)

    Drug: GC33

Interventions

  • DrugPlacebo

    iv Days 1 and 8, and every 2 weeks thereafter

  • DrugGC33

    1600 mg iv Day 1 and 8, and every 2 weeks thereafter

    Also known as: RO5137382

06

What researchers measure

Primary outcomes

  1. Progression-free survival (tumor assessments according to RECIST criteria)

    Time frame: approximately 24 months

Secondary outcomes

  1. Overall survival

    Time frame: approximately 32 months

  2. Time to progression (TTP): Time from randomization to first documented disease progression

    Time frame: approximately 24 months

  3. Disease control rate (DCR): Complete response, partial response or stable disease lasting at least 6 weeks

    Time frame: approximately 24 months

  4. Safety: Incidence of adverse events

    Time frame: approximately 24 months

  5. Pharmacokinetics: Serum concentrations (Cmax,Cmin)

    Time frame: Multiple sampling pre- and post-dose Days 1 and 8 Cycle 1, Day 1 Cycle 6, pre-dose Day 1 Cycles 2-11

  6. GPC-3 expression in tumor tissue (biopsy) by immunohistochemistry (IHC) assay

    Time frame: at screening

07

Study locations

57 sites
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • National Cancer Institute; Ctr for Cancer Research
    Bethesda, Maryland 20889-0001, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Washington Univ School of Med; Barnes-Jewish Hospital; Siteman Cancer Center
    Saint Louis, Missouri 63110, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Vanderbilt Medical Center
    Nashville, Tennessee 37232-7610, United States
  • Swedish Cancer Inst.
    Seattle, Washington 98104, United States
  • Hospital Erasme
    Bruxelles, 1070, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • Hotel Dieu; Medecine A
    Angers, 49033, France
  • CHU de GRENOBLE; UF de Cancérologie
    Grenoble, 38 043, France
  • Aphm; Hopital De La Conception
    Marseille, 13385, France
  • Hopital de L'Archet; Pole de Reference Hepatite C
    Nice, 06202, France
  • Hôpital Saint Antoine; Service Hépathologie
    Paris, 75571, France
  • Hopital Purpan;Gastro Enterologie Hepatologie
    Toulouse, 31059, France
  • Hôpital d'Adultes; Service hépato-gastro-entérologie
    Vandoeuvre-les-nancy, 54511, France
  • Charité Uni.-medizin Berlin, Campus Virchow-Klinikum; Med. Klinik m.S. Hepatologie Gastroenterologie
    Berlin, 13353, Germany
  • Klinik Johann Wolfgang von Goethe Uni; Zentrum der Inneren Medizin; Medizinische Klinik I
    Frankfurt Am Main, 60590, Germany
  • Uni Heidelberg Med. Klinik; Innere Medizin IV
    Heidelberg, 69120, Germany
  • Universitätsklinikum Leipzig
    Leipzig, 04103, Germany
  • Klinikum rechts der Isar der TU München; Klinikapotheke
    Muenchen, 81675, Germany
  • Queen Mary Hospital; Dept of Surgery
    Pokfulam, Hong Kong
  • Prince of Wales Hosp; Dept. Of Clinical Onc
    Shatin, Hong Kong
  • Azienda Ospedaliera G. Rummo; Unità Operativa di Oncologia Medica 1
    Benevento, Campania 82100, Italy
  • Policlinico Universitario Agostino Gemelli
    Roma, Lazio 00168, Italy
  • Fondazione IRCCS Ospedale Maggiore Policlinico; Gastroenterologia
    Milano, Lombardia 20122, Italy
  • National Cancer Center Hospital East
    Chiba, 277-8577, Japan
  • Kanazawa University Hospital
    Ishikawa, 920-8641, Japan
  • Kanagawa Cancer Center
    Kanagawa, 241-8515, Japan
  • Kindai University Hospital
    Osaka, 589-8511, Japan
  • National Cancer Center Hospital
    Tokyo, 104-0045, Japan
  • Kyorin University Hospital
    Tokyo, 181-8611, Japan
  • Pusan University Hospital
    Busan, 602-739, Korea, Republic of
  • National Cancer Center
    Gyeonggi-do, 10408, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Seoul St Mary's Hospital
    Seoul, 06591, Korea, Republic of
  • Auckland Hospital; New Zealand Liver Transplant Unit
    Auckland, 100, New Zealand
  • National Cancer Centre; Medical Oncology
    Singapore, 169610, Singapore
  • Hospital Universitario Marques de Valdecilla; Servicio de Oncologia
    Santander, Cantabria 39008, Spain
  • Hospital Universitari Vall d'Hebron; Servicio de Hepatologia
    Barcelona, 08035, Spain
  • Hospital Clínic i Provincial; Servicio de Hematología y Oncología
    Barcelona, 08036, Spain
  • Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
    Madrid, 28007, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28007, Spain
  • Hospital Universitario Clínico San Carlos; Servicio de Oncologia
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre; Servicio de Oncologia
    Madrid, 28041, Spain
  • Hospital Universitario Miguel Servet; Servicio Hematologia
    Zaragoza, 50009, Spain
  • Chang Gung Memorial Foundation - Kaohsiung
    Kaohsiung, 00833, Taiwan
  • Taichung Veterans Gen Hosp
    Taichung, 40705, Taiwan
  • National Cheng Kung Univ Hosp
    Tainan, 00704, Taiwan
  • Taipei Veterans General Hospital
    Taipei City, 112, Taiwan
  • National Taiwan Uni Hospital; Dept of Oncology
    Taipei, 100, Taiwan
  • The Clatterbridge Cancer Ctr NHS Foundation Trust
    Bebington, CH63 4JY, United Kingdom
  • Royal Free Hospital; Dept of Oncology
    London, NW3 2QG, United Kingdom
  • King'S College Hospital; Haematology
    London, SE5 9RS, United Kingdom
08

References and documents

Publications

  • Pradier MF, Reis B, Jukofsky L, Milletti F, Ohtomo T, Perez-Cruz F, Puig O. Case-control Indian buffet process identifies biomarkers of response to Codrituzumab. BMC Cancer. 2019 Mar 28;19(1):278. doi: 10.1186/s12885-019-5472-0. PubMed 30922327 ↗
  • Abou-Alfa GK, Puig O, Daniele B, Kudo M, Merle P, Park JW, Ross P, Peron JM, Ebert O, Chan S, Poon TP, Colombo M, Okusaka T, Ryoo BY, Minguez B, Tanaka T, Ohtomo T, Ukrainskyj S, Boisserie F, Rutman O, Chen YC, Xu C, Shochat E, Jukofsky L, Reis B, Chen G, Di Laurenzio L, Lee R, Yen CJ. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol. 2016 Aug;65(2):289-95. doi: 10.1016/j.jhep.2016.04.004. Epub 2016 Apr 13. PubMed 27085251 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2012 to primary completion in Aug 2015, 42 months.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 42 months is above that.

Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2012
First posted
Jan 10, 2012
StartActual
Feb 2, 2012
Primary completionActual
Aug 20, 2015
CompletionActual
Aug 20, 2015
Last update
Apr 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01507168
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 10, 2012
Start date
Feb 2, 2012
Primary completion
Aug 20, 2015
Completion
Aug 20, 2015
Last update
Apr 3, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Codrituzumab

Start the discussion